Corcept Therapeutics Incorporated (CORT)
- Previous Close
26.60 - Open
26.83 - Bid 27.00 x 100
- Ask 27.21 x 100
- Day's Range
26.62 - 27.48 - 52 Week Range
20.84 - 34.28 - Volume
370,311 - Avg. Volume
1,105,080 - Market Cap (intraday)
2.822B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
25.82 - EPS (TTM)
1.05 - Earnings Date Jul 31, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
43.60
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
www.corcept.comRecent News: CORT
Performance Overview: CORT
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CORT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CORT
Valuation Measures
Market Cap
2.77B
Enterprise Value
2.36B
Trailing P/E
25.35
Forward P/E
37.17
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.61
Price/Book (mrq)
5.06
Enterprise Value/Revenue
4.51
Enterprise Value/EBITDA
19.10
Financial Highlights
Profitability and Income Statement
Profit Margin
22.54%
Return on Assets (ttm)
11.96%
Return on Equity (ttm)
21.91%
Revenue (ttm)
523.53M
Net Income Avi to Common (ttm)
117.2M
Diluted EPS (ttm)
1.05
Balance Sheet and Cash Flow
Total Cash (mrq)
410.76M
Total Debt/Equity (mrq)
0.01%
Levered Free Cash Flow (ttm)
123.86M
Research Analysis: CORT
Company Insights: CORT
CORT does not have Company Insights